Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01425970 · ClinicalTrials.gov registry record · Phase 2
Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
NCT01425970 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 210 participants.
The verdict
NCT01425970, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
Study Summary
Part A: The purpose of this study is to evaluate the safety and tolerability of INX-08189 and placebo with Peginterferon alfa-2a and Ribavirin during 12 weeks of treatment Part B: The purpose of this study is to evaluate the safety and tolerability of INX-08189 with Ribavirin or INX-08189 with Daclatasvir or INX-08189 with Daclatasvir and Ribavirin
Interventions
- DRUG INX-08189
- DRUG Placebo matching with INX-08189
- BIOLOGICAL Pegylated interferon alfa-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01425970
The ClinicalTrials.gov registry entry for NCT01425970 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which INX-08189 is the first listed.
NCT01425970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01425970 about?
NCT01425970 is a clinical study titled "Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin". Part A: The purpose of this study is to evaluate the safety and tolerability of INX-08189 and placebo with Peginterferon alfa-2a and Ribavirin during 12 weeks of treatment Part B: The purpose of this study is to evaluate the safety and tolerability of INX-08189 with Ribavirin or INX-08189 with Dacl...
What is the current status of trial NCT01425970?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2012-05. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01425970?
The interventions under investigation include: INX-08189 (DRUG), Placebo matching with INX-08189 (DRUG), Pegylated interferon alfa-2a (BIOLOGICAL).
Who is sponsoring clinical trial NCT01425970?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.